SEC Form 4 · accession 0001546927-15-000263
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Camber Capital Management LLC
10% Owner
Period of report
Oct 19, 2015
Accepted (ET)
Oct 20, 2015 · 2:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001006281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 19, 2015 | P | 4,000,000 | $1.00 | A | 13,274,577 | I | See Footnotes |
| Common StockF1,F3,F4 | Oct 19, 2015 | P | 423 | $1.03 | A | 13,275,000 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities reported herein for Camber Capital Management LLC (the "LLC" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 25, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.
- F2Of the securities reported for this transaction, 3,862,000 shares of Common Stock were purchased for the account of the Master Fund, 27.200 shares of Common Stock were purchased for the account of the Fund, and 110,800 shares of Common Stock were purchased for the account of the Managed Account.
- F3Of the securities reported for this transaction, 408 shares of Common Stock were purchased for the account of the Master Fund, 3 shares of Common Stock were purchased for the account of the Fund, and 12 shares of Common Stock were purchased for the account of the Managed Account.
- F4As of the closing of trading on October 19, 2015, 12,815,503 shares of Common Stock were held for the account of the Master Fund, 90,260 shares of Common Stock were held for the account of the Fund, and 369,237 shares of Common Stock were held for the account of the Managed Account.